Pratik Sinha1,2, Carolyn S Calfee1,2,3. 1. Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine. 2. Department of Anesthesia. 3. Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California, USA.
Abstract
PURPOSE OF REVIEW: To provide an overview of the current research in identifying homogeneous subgroups and phenotypes in ARDS. RECENT FINDINGS: In recent years, investigations have used either physiology, clinical data, biomarkers or a combination of these to stratify patients with ARDS into distinct subgroups with divergent clinical outcomes. In some studies, there has also been evidence of differential treatment response within subgroups. Physiologic approaches include stratification based on P/F ratio and ventilatory parameters; stratification based on P/F ratio is already being employed in clinical trials. Clinical approaches include stratification based on ARDS risk factor or direct vs. indirect ARDS. Combined clinical and biological data has been used to identify two phenotypes across five cohorts of ARDS, termed hyperinflammatory and hypoinflammatory. These phenotypes have widely divergent clinical outcomes and differential response to mechanical ventilation, fluid therapy, and simvastatin in secondary analysis of completed trials. Next steps in the field include prospective validation of inflammatory phenotypes and integration of high-dimensional 'omics' data into our understanding of ARDS heterogeneity. SUMMARY: Identification of distinct subgroups or phenotypes in ARDS may impact future conduct of clinical trials and can enhance our understanding of the disorder, with potential future clinical implications.
PURPOSE OF REVIEW: To provide an overview of the current research in identifying homogeneous subgroups and phenotypes in ARDS. RECENT FINDINGS: In recent years, investigations have used either physiology, clinical data, biomarkers or a combination of these to stratify patients with ARDS into distinct subgroups with divergent clinical outcomes. In some studies, there has also been evidence of differential treatment response within subgroups. Physiologic approaches include stratification based on P/F ratio and ventilatory parameters; stratification based on P/F ratio is already being employed in clinical trials. Clinical approaches include stratification based on ARDS risk factor or direct vs. indirect ARDS. Combined clinical and biological data has been used to identify two phenotypes across five cohorts of ARDS, termed hyperinflammatory and hypoinflammatory. These phenotypes have widely divergent clinical outcomes and differential response to mechanical ventilation, fluid therapy, and simvastatin in secondary analysis of completed trials. Next steps in the field include prospective validation of inflammatory phenotypes and integration of high-dimensional 'omics' data into our understanding of ARDS heterogeneity. SUMMARY: Identification of distinct subgroups or phenotypes in ARDS may impact future conduct of clinical trials and can enhance our understanding of the disorder, with potential future clinical implications.
Authors: Herbert P Wiedemann; Arthur P Wheeler; Gordon R Bernard; B Taylor Thompson; Douglas Hayden; Ben deBoisblanc; Alfred F Connors; R Duncan Hite; Andrea L Harabin Journal: N Engl J Med Date: 2006-05-21 Impact factor: 91.245
Authors: Giacomo Bellani; John G Laffey; Tài Pham; Eddy Fan; Laurent Brochard; Andres Esteban; Luciano Gattinoni; Frank van Haren; Anders Larsson; Daniel F McAuley; Marco Ranieri; Gordon Rubenfeld; B Taylor Thompson; Hermann Wrigge; Arthur S Slutsky; Antonio Pesenti Journal: JAMA Date: 2016-02-23 Impact factor: 56.272
Authors: Carolyn S Calfee; David R Janz; Gordon R Bernard; Addison K May; Kirsten N Kangelaris; Michael A Matthay; Lorraine B Ware Journal: Chest Date: 2015-06 Impact factor: 9.410
Authors: Katie R Famous; Kevin Delucchi; Lorraine B Ware; Kirsten N Kangelaris; Kathleen D Liu; B Taylor Thompson; Carolyn S Calfee Journal: Am J Respir Crit Care Med Date: 2017-02-01 Impact factor: 21.405
Authors: Roy G Brower; Michael A Matthay; Alan Morris; David Schoenfeld; B Taylor Thompson; Arthur Wheeler Journal: N Engl J Med Date: 2000-05-04 Impact factor: 91.245
Authors: Ashish Agrawal; Michael A Matthay; Kirsten N Kangelaris; John Stein; Jeffrey C Chu; Brandon M Imp; Alfredo Cortez; Jason Abbott; Kathleen D Liu; Carolyn S Calfee Journal: Am J Respir Crit Care Med Date: 2013-04-01 Impact factor: 21.405
Authors: Carolyn S Calfee; Mark D Eisner; Polly E Parsons; B Taylor Thompson; Edward R Conner; Michael A Matthay; Lorraine B Ware Journal: Intensive Care Med Date: 2008-08-01 Impact factor: 17.440
Authors: Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg Journal: N Engl J Med Date: 2008-10-23 Impact factor: 91.245
Authors: Konrad Peukert; Mario Fox; Susanne Schulz; Caroline Feuerborn; Stilla Frede; Christian Putensen; Hermann Wrigge; Beate Mareike Kümmerer; Sascha David; Benjamin Seeliger; Tobias Welte; Eicke Latz; Dennis Klinman; Christoph Wilhelm; Folkert Steinhagen; Christian Bode Journal: Am J Respir Crit Care Med Date: 2021-07-01 Impact factor: 21.405
Authors: Lieuwe D J Bos; Antonio Artigas; Jean-Michel Constantin; Laura A Hagens; Nanon Heijnen; John G Laffey; Nuala Meyer; Laurent Papazian; Lara Pisani; Marcus J Schultz; Manu Shankar-Hari; Marry R Smit; Charlotte Summers; Lorraine B Ware; Raffaele Scala; Carolyn S Calfee Journal: Eur Respir Rev Date: 2021-02-02
Authors: Mohamed D Hashem; Ramona O Hopkins; Elizabeth Colantuoni; Victor D Dinglas; Pratik Sinha; Lisa Aronson Friedman; Peter E Morris; James C Jackson; Catherine L Hough; Carolyn S Calfee; Dale M Needham Journal: Thorax Date: 2021-06-10 Impact factor: 9.139